|
WO2006069765A2
|
|
Secreted polypeptide species involved in multiple sclerosis
|
|
WO2006069739A2
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006029838A2
|
|
Secreted polypeptide species involved in alzheimer’s disease
|
|
WO2006029852A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006029839A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006029840A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005590A1
|
|
Polypeptide for the treatment of neurological disorders
|
|
WO2006005591A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005582A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005583A2
|
|
Secreted polypeptide species involved in multiple sclerosis
|
|
WO2006005586A2
|
|
New polypeptide species specific to cerebrospinal fluid
|
|
WO2006005585A2
|
|
Secreted polypeptide species differentially expressed during pregnancy
|
|
WO2006005592A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005584A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005589A2
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005588A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005587A1
|
|
Polypeptide species useful for the treatment of neurological disorders
|
|
WO2006005538A1
|
|
Polypeptide for treatment of neurological disorders
|
|
WO2004063215A2
|
|
Improve peptide charge state assignment in a high-throughput ms/ms environment
|
|
EP1535053A2
|
|
Multi-dimensional chromatography system for proteomics
|
